These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19187414)

  • 1. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia.
    Molnar FJ; Man-Son-Hing M; Fergusson D
    J Am Geriatr Soc; 2009 Mar; 57(3):536-46. PubMed ID: 19187414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
    Burback D; Molnar FJ; St John P; Man-Son-Hing M
    Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective.
    Broich K
    Int Psychogeriatr; 2007 Jun; 19(3):509-24. PubMed ID: 17433121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydergine for dementia.
    Olin J; Schneider L; Novit A; Luczak S
    Cochrane Database Syst Rev; 2001; (2):CD000359. PubMed ID: 11405961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using a distribution-based approach and systematic review methods to derive minimum clinically important differences.
    Watt JA; Veroniki AA; Tricco AC; Straus SE
    BMC Med Res Methodol; 2021 Feb; 21(1):41. PubMed ID: 33637039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive pharmacotherapy of Alzheimer's disease and other dementias.
    Herrmann N
    Can J Psychiatry; 2002 Oct; 47(8):715-22. PubMed ID: 12420649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of galantamine in Alzheimer's disease associated with vascular dementia (according to the study of T. Erkinjuntti group)].
    Damulin IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(5):65-7. PubMed ID: 19938276
    [No Abstract]   [Full Text] [Related]  

  • 10. Global measures: utility in defining and measuring treatment response in dementia.
    Reisberg B
    Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
    Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
    Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacologic treatment of Alzheimer's disease: a guide for the general psychiatrist.
    Flint AJ; van Reekum R
    Can J Psychiatry; 1998 Sep; 43(7):689-97. PubMed ID: 9773218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer's Disease over a Three-Year Period: Kuopio ALSOVA Study.
    Törmälehto SM; Martikainen JA; Väätäinen ST; Hallikainen IT; Hallikainen M; Bell JS; Koivisto AM
    J Alzheimers Dis; 2015; 48(4):1033-41. PubMed ID: 26444756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease.
    Doody R; Wirth Y; Schmitt F; Möbius HJ
    Dement Geriatr Cogn Disord; 2004; 18(2):227-32. PubMed ID: 15256834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of delusions in Alzheimer's disease--response to pharmacotherapy.
    Fischer C; Bozanovic R; Atkins JH; Rourke SB
    Dement Geriatr Cogn Disord; 2006; 22(3):260-6. PubMed ID: 16902281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of global scales.
    Oremus M; Perrault A; Demers L; Wolfson C
    J Geriatr Psychiatry Neurol; 2000; 13(4):197-205. PubMed ID: 11128059
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.